Abstract
Introduction

Transplantation of adult bone marrow cells (BMCs) is associated with improvement in left ventricular (LV) structure and function. Following promising results in animal studies, this therapeutic approach has been quickly translated into clinical trials and several different types of BMCs have been used for this purpose
. However, a meta-analysis of the results of these small clinical trials indicates that the benefits of BMC therapy are only modest [1] . A vigorous effort has therefore been mounted to identify not only the optimal cell types, but also possible modifications prior to transplantation that may improve the outcome of BMC therapy. [2] [3] [4] [3, 5] , are mobilized after acute myocardial infarction (MI) [6] and promote cardiac repair following transplantation into the infarct border zone in vivo [7] . In our previous study [7] [7] we transplanted only 10,000 freshly isolated, non-expanded VSEL-SCs [7] . 
Recent studies from our laboratories have characterized a population of pluripotent CXC chemokine receptor (CXCR) 4ϩ cells that reside in the adult bone marrow, are non-haematopoietic and are able to differentiate into cells of various lineages, including cardiomyocytes and endothelial cells
VSEL-SC transplantation improved LV function and dimensions but was associated with minimal or no differentiation of VSEL-SCs into cardiomyocytes at 35 days after MI; because of the scarcity of VSEL-SCs in the bone marrow and our prior inability to expand them effectively, in that investigation
Clinical translation of this therapy, however, will require transplantation of much greater numbers of cells, particularly when intracoronary infusion (instead if intramyocardial injection) is used. Consequently, before this new promising cell type can find clinical application in patients with ischemic heart disease, it is important to develop methods to expand VSEL-SCs in culture while maintaining therapeutic efficacy. Recently, we have been able to expand VSEL-SCs by culturing them on C2C12 myoblast cells. Thus, in the present study we examined whether VSEL-SCs expanded with this method exert salubrious effects on post-MI LV dysfunction and remodelling, analogous to those previously observed with non-expanded VSEL-SCs [7]. Because we have previously observed that incubation in a cardiomyogenic medium (containing transforming growth factor-␤1 [TGF-␤1], vascular endothelial growth factor [VEGF], basic fibroblast growth factor [bFGF] and insulin-like growth factor-1 [IGF-1]) promotes differentiation of freshly isolated VSEL-SCs towards
Experimental protocol
This study was performed in a well-established murine model of MI [7] [8] [9] . The experimental protocol is summarized in Figure 1 [9, 10] . The midsection was used to measure LV diameter. The thickness of the infarct wall, septal wall and posterior wall was calculated in serial sections and averaged [9, 10] . An average sarcomere length of 2.1 m was utilized in all cases to correct the raw measurements of LV anatomical parameters [11] . For the assessment of cardiomyocyte cross-sectional area, digital images were acquired from trichrome-stained myocardial sections. Cardiomyocyte cross-sectional area was measured in transversely sectioned myocytes with a circular profile and a central nucleus [7, 12] . On average, a total of 100 myocytes were measured in each heart. All morphometric analyses were performed by investigators who were blind to the treatment allocation. [9, 13] . Colocalization of cell-specific markers with EGFP was used to identify cells that originated from BMCs [9, 14] .
Myocardial infarction and cell transplantation
Immunohistochemistry
Nuclei were identified with 4Ј-6-diamidino-2-phenylindole (DAPI).
For the assessment of capillary density [12, 15] , sections were stained with an anti-CD31 (Santa Cruz Biotechnology, Inc.) primary antibody followed by the addition of a tetramethylrhodamine isothiocyanate (TRITC)-conjugated secondary antibody [7, 13] [7, 9] . [7, 9, 10] . (Fig. 4) (Fig. 4E) . (Fig. 6) . These results were corroborated by the echocardiographic estimates of LV mass, which were significantly increased from baseline to 35 days in groups I and II but not in group III; in the latter group, the LV mass was 24% smaller than in group I (PϽ0.05) (Fig. 6E) . Together, these data indicate that transplantation of expanded and pre-incubated VSELSCs is associated with attenuation of myocyte hypertrophy.
Statistical analysis
Transplantation of pre-incubated VSEL-SCs attenuates LV systolic dysfunction
Before coronary occlusion (baseline), all parameters of LV function, measured by echocardiography, were similar in groups I, II and III (Fig. 4). At 48 hrs after cell transplantation (96 hrs after reperfusion), the degree of LV systolic functional impairment was also similar among the groups (Fig. 4), indicating that both the injury sustained during ischemia/reperfusion and that associated with intramyocardial injection were comparable. In mice that received vehicle (group I) or expanded but untreated VSEL-SCs (group II), there was further functional deterioration between 96 hrs and 35 days after reperfusion
Transplantation of pre-incubated VSEL-SCs attenuates LV expansion
The extent of LV remodelling at 35 days after infarction was assessed both morphometrically and echocardiographically (Fig. 5). By morphometry, the differences among groups did not reach statistical significance (Fig. S1). By echocardiography, LV enddiastolic volume at 35 days in group III (63 Ϯ 11 l) was 26% smaller compared with group I (86 Ϯ 8 l), albeit without statistical significance (Fig. 5D). These data suggest a possible trend towards
Fig. 3 Myocardial infarct size. Myocardial infarct area fraction [(infarct area/LV area) ϫ 100] assessed from Masson's trichrome-stained hearts in groups I, II and III, which were treated with vehicle, expanded untreated VSEL-SCs and expanded pre-incubated VSEL-SCs, respectively. Data are means Ϯ S.E.M. n ϭ 7-11 mice/group.
Fig. 4 Impact of cell therapy on LV function. (A)-(C) Representative M-mode images at 35 days after coronary occlusion/reperfusion from mice that were given vehicle (group I) (A), expanded and untreated VSEL-SCs (group II) (B) and expanded pre-incubated VSEL-SCs (group III) (C). Compared with the hearts in groups I and II, the heart in group III exhibited a smaller LV cavity, a thicker infarct wall and improved motion of the infarct wall. (D-E) Quantitative echocardiographic analysis revealed improvement in LV functional parameters following transplantation of pre-incubated VSEL-SCs at 35 days after MI. Data are means Ϯ S.E.M. n ϭ 7-11 mice/group. *PϽ0.05 versus group I at 35 days. improvement in post-MI LV expansion in mice that were given preincubated VSEL-SCs as compared with vehicle-treated mice.
Transplantation of pre-incubated VSEL-SCs attenuates LV hypertrophy
Myocyte regeneration
Cardiomyogenic specification of transplanted VSEL-SCs was inferred by concomitant positivity for ␣-sarcomeric actin and EGFP [9, 17] . Although scattered EGFP ϩ /␣-sarcomeric actin ϩ cells were identified in the peri-infarct zone in both groups II and III (Fig. 7) ,
the number of such cells was very small in both groups and the morphology did not resemble that of adult myocytes, indicating that the functional and structural benefits of VSEL-SCs could not be accounted for by their differentiation into new cardiac myocytes.
Impact of cell therapy on capillary density, myocyte apoptosis and myocyte cycling
Either in the infarct border zone or in the non-ischemic zone, there was no significant difference among the three groups with respect to capillary density (Fig. S2) [1] , the improvement in LV ejection fraction and the reduction in infarct scar size observed in clinical trials have been relatively modest [1] , prompting the search for specific cell types that may confer more consistent benefits. We have previously shown that VSEL-SCs, a recently discovered population of pluripotent stem cells found in adult bone narrow [3, 4, 6] , can be effectively used to alleviate post-MI cardiac dysfunction and remodelling in mice [7] . However, if this new form of cell therapy is to be used in humans, methods need to be developed that will enable expansion of VSEL-SCs prior to transplantation, because their numbers in the bone marrow are very low [3] . In this study we explored the feasibility of expanding VSEL-SCs on a C2C12 cell feeder layer prior to injection into infarcted hearts. [18, 19] , and because many cells are lost following myocardial transplantation as a result of washout and death [20, 21] , injecting large numbers of cells is important, at least in principle. VSEL-SCs are very rare in the adult bone marrow (~0.01% of all nucleated BMCs); consequently, in our previous study [7] we were unable to inject more than 10,000 freshly isolated VSEL-SCs in each mouse, a number that may have been [2, 3, 5] . As mentioned above, in our previous study [7] [22] , bFGF [23] and IGF-1 [24] , have been implicated in cardiogenesis in embryonic developmental studies. These factors have also been used successfully to induce cardiac differentiation of various embryonic and adult cells in vitro [25, 26] A similar pattern has been observed in several other studies [7, 29, 30] . Indeed, whether differentiation of transplanted cells into cells of cardiac and vascular lineages serves as the primary mechanism of infarct repair with cell therapy remains controversial [31] [32] [33] (Fig. 6) . Further studies will be necessary to fully characterize the genetic properties of expanded VSEL-SCs [36] and to identify the molecular mechanisms via which exposure to cardiomyogenic medium influenced the reparative properties of expanded VSEL-SCs.
, Ki67 immunoreactivity (for identification of cycling cells) (Fig. S3) and immunoreactivity for the hairpin-1 probe (for detection of apoptosis) (data not shown).
Discussion
Although basic as well as clinical studies indicate that transplantation of adult BMCs induces cardiac repair and improves LV function after MI
Our salient findings are the following: (i) in a murine model of reperfused MI, intramyocardial injection of 10 5 VSEL-SCs expanded and then pre-incubated in cardiomyogenic medium resulted in improvement in LV function and attenuation of LV hypertrophy; (ii) in contrast, injection of the same number of expanded but not pre-incubated VSEL-SCs failed to impart any beneficial effect and (iii) at 35 days after MI, very few cells derived from the transplanted VSEL-SCs were found that expressed markers of cardiomyocytic or endothelial differentiation, implying that the salubrious effects of pre-incubated VSEL-SCs are mediated by paracrine mechanisms. Together, these results demonstrate that VSEL-SCs expanded in vitro can be used to alleviate cardiac dysfunction and remodelling after MI, but for this strategy to be effective, the cells need to be exposed to a combination of cardiogenic growth factors and cytokines (TGF-␤1, VEGF, bFGF and IGF-1) prior to transplantation. Because the number of cells transplanted may be a major determinant of their efficacy
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